Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study)

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 245, Issue 9, 2007, Pages 1273-1280

  Costa, Rogério A ^a   Jorge, Rodrigo ^b   Calucci, Daniela ^a   Melo Jr , Luiz A S ^a   Cardillo, José A ^a   Scott, Ingrid U ^c  

^a Hospital de Olhos de Araraquara   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Choroid; Laser; Neovascularization; Pegaptanib; Ranibizumab; Vascular endotelhial growth factor (VEGF)

Indexed keywords

ACETAZOLAMIDE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; FLUORESCEIN; PHENYLEPHRINE; TETRACAINE; TROPICAMIDE;

AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CORNEA INJURY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE TOXICITY; FEASIBILITY STUDY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LENS; MALE; OPEN STUDY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEITIS; VISION; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 34548047705     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-007-0557-x     Document Type: Article

References (50)

1. Miller JW, Schmidt-Erfurth U, Sickenberg M et al (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161-1173
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report no. 1. Arch Ophthalmol 117:1329-1345
3. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-TAP report no. 2. Arch Ophthalmol 119:198-207
4. Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 108:841-852
5. Blinder KJ, Blumenkranz MS, Bressler NM et al (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 110:667-673
6. Gragoudas ES, Adamis AP, Cunningham ET Jr, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816
7. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group (2005) Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis. Retina 25:815-827
8. Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431
9. Brown DM, Kaiser PK, Michels M, ANCHOR Study Group et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444
10. Rechtman E, Danis RP, Pratt LM, Harris A (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 88:344-347
11. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517-1525
12. Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301-304
13. Nicolo M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G (2006) Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 26:58-64
14. Viola F, Morescalchi F, Ratiglia R, Staurenghi G (2006) Ptosis following an intravitreal injection of triamcinolone acetonide. Eye 2006 Feb 24 [Epub ahead of print]
15. Aggermann T, Stolba U, Brunner S, Binder S (2006) Endophthalmitis with retinal necrosis following intravitreal triamcinolone acetonide injection. Ophthalmologica 220:131-133
16. Quiram PA, Gonzales CR, Schwartz SD (2006) Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 141:580-582
17. Saidel MA, Berreen J, Margolis TP (2005) Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol 140:1141-1143
18. Yang CS, Chen MJ, Chou CK, Hsu WM (2005) Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmologica 219:413-415
19. Gupta OP, Boynton JR, Sabini P, Markowitch W Jr, Quatela V (2003) Proptosis after retrobulbar corticosteroid injections. Ophthalmology 110:443-447
20. Dal Canto AJ, Downs-Kelly E, Perry JD (2005) Ptosis and orbital fat prolapse after posterior sub-Tenon's capsule triamcinolone injection. Ophthalmology 112:1092-1097
21. Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK (2002) Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol 134:132-134
22. Agrawal S, Agrawal J, Agrawal TP (2003) Conjunctival ulceration following triamcinolone injection. Am J Ophthalmol 136:539-540
23. Eyetech Study Group (2002) Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143-152
24. Eyetech Study Group (2003) Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 110:979-986
25. Kim IK, Husain D, Michaud N et al (2006) Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 47:357-363
26. Husain D, Kim I, Gauthier D et al (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509-516
27. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473-4480
28. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
29. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
30. Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262-269
31. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26:270-274
32. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257-261
33. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331-335
34. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336-339
35. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372
36. Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-390
37. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU (2006) Intravitreal bevacizumab (Avastin) for choroidal neovascularization caused by age-related macular degeneration (IBeNA Study): Results of a dose-escalation study. Invest Ophthalmol Vis Sci 47:4569-4578
38. Iturralde D, Spaide RF, Meyerle CB et al (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279-284
39. Paula JS, Jorge R, Costa RA, Rodrigues MLV, Scott IU (2006) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84:556-557
40. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278
41. Jorge R, Costa RA, Calucci D, Cintra L, Scott IU (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBePe Study). Retina 26:1006-1013
42. Bird AC, Bressler NM, Bressler SB et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39:367-374
43. Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial. VIP report no 1. Ophthalmology 108:841-852
44. Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem Photobiol 55:145-157
45. Grossweiner LI (1994) The science of phototherapy. CRC Press, Boca Raton, FL, USA, pp 27-49, 139-155, 175-177
46. Costa RA, Farah ME, Cardillo JA, Calucci DS, Williams GA (2003) Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy of subfoveal choroidal neovascularization. Retina 23:159-165
47. Schmidt-Erfurth U, Laqua H, Schloetzer-Schrehard U et al (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835-843
48. Gelisken F, Lafaut BA, Inhoffen W et al (2004) Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 88:207-211
49. Schnurrbusch UEK, Welt K, Horn LC et al (2001) Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 85:1086-1091
50. Ghazi NG, Jabbour NM, De la Cruz ZC et al (2001) Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 21:478-486